With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC)

Molecular characterization of appendiceal goblet cell carcinoid

Molecular landscape of gastric cancer (GC) harboring mutations of histone methyltransferases

Non-urothelial bladder cancer genomic alterations and patient outcomes

Molecular Profiling of Aggressive Variant Urothelial Carcinoma

Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC)

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

Tumor Mutational Burden Is Site Specific in Non–Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases

The current state of molecular testing in the treatment of patients with solid tumors, 2019

Clinical, Pathological and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer